SPYRE THERAPEUTICS, INC. (SYRE) Free cash flow 2016–2024
SPYRE THERAPEUTICS, INC. (SYRE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$157.4MFY2024 · since FY2016: -$19.1M → -$157.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$157.4M | -57.6% |
| FY2023 | -$99.9M | -24.6% |
| FY2022 | -$80.2M | -47.7% |
| FY2021 | -$54.3M | +32.2% |
| FY2020 | -$80.1M | -19.2% |
| FY2019 | -$67.2M | -106.0% |
| FY2018 | -$32.6M | -29.3% |
| FY2017 | -$25.2M | -32.4% |
| FY2016 | -$19.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SYRE financial trends
SYRE RevenueSYRE Net incomeSYRE Net marginSYRE Gross profitSYRE Gross marginSYRE Operating incomeSYRE Operating marginSYRE Operating cash flowSYRE Capital expendituresSYRE Return on equitySYRE Stock buybacksSYRE Dividends paidSYRE Total assetsSYRE Total liabilitiesSYRE Shareholders’ equitySYRE overview →